Stock Movers Boeing Gets an Upgrade, Moderna Wins FDA Vaccine Approval
Jun 2, 2025
Boeing’s stock is on the rise after a Bank of America upgrade, fueled by strategic trade dynamics. The company’s aircraft are becoming essential in new trade deals. Meanwhile, Moderna sees its shares climb following FDA approval of a new COVID vaccine tailored for adults over 65 and high-risk individuals. Analysts are divided on how this will affect future sales. Both companies showcase the impactful relationship between market reactions and regulatory decisions.
AI Snips
Chapters
Transcript
Episode notes
Boeing's Market Revival
- Boeing shares rose notably following an upgrade by Bank of America to a buy rating, with the highest price target on the street at $260.
- The company's aircraft benefited from trade deals under the Trump administration, helping the stock rebound with a 20% gain year to date.
737 Deliveries Drive Boeing Cash Flow
- Boeing's cash flow is driven by increasing deliveries of the 737 model, which is crucial to its production ramp-up.
- Continued production progress is fundamental to sustaining its financial and stock performance.
Moderna Vaccine Approval Impact
- Moderna shares rose after FDA approval of its second-generation COVID vaccine for vulnerable adults.
- Analysts view this as an incremental win with limited expected sales boost due to political and market factors.